PDX model details
PDX ID | 27.1A Cx |
---|---|
Host Strain(and Source) | NSG Source: Monash University |
Host Strain Immune system Humanized | NO |
Host Type | Castrate |
Graft Site | Subcutaneous |
Current Generation (* indicates number of generations grown in Castrate host) |
29 (8*) |
Average PDX Generation Time (days +/- SEM) | 82 ± 8 |
Tumor preparation | Tumor solid |
Tumor Characterization Technology | Histology, IHC, STR profiling, targeted DNA sequencing, RNAseq |
Tumor confirmed not to be of Mouse/EBV origin | Yes; negative for CD45 and/or positive for human CK8/18 and/or human mitochondria by IHC |
Passage QA performed | Routine QA every 2-3 passages |
Associated meta data | |
PDX model availability | Yes (fixed, frozen or cryopreserved tissue) |
Governance restriction for distribution | Available to investigators with appropriate ethics approvals, approved EOI from MURAL committee, and material transfer agreements |
Pubmed ID | 34413304; 30049486 |
Markers | 27.1A Cx |
---|---|
AR | Y |
PSA | Y |
PSMA | Y |
NE | N |
ERG | N |
This table displays curated CNVs
PDX ID | Gene Symbol | CNV Log2 | CNV Copy | CNV Call | Experiments name | Platform | Reference genome |
---|---|---|---|---|---|---|---|
27.1A Cx | SETDB1 | 0.586547 | 3.0033 | gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
27.1A Cx | MET | 0.584798 | 2.99966 | gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
27.1A Cx | BRAF | 0.584798 | 2.99966 | gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
27.1A Cx | EZH2 | 0.584798 | 2.99966 | gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
27.1A Cx | KMT2C | 0.584798 | 2.99966 | gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
27.1A Cx | CHD1 | -26.9288 | 0.0000000157 | homdel | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
27.1A Cx | RB1 | -28.0016 | 0.00000000744 | homdel | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
27.1A Cx | AR | -4.02605 | 0.0613816 | homdel | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
27.1A Cx | PAX6 | -1.02752 | 0.981105 | loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
27.1A Cx | MGA | -0.931673 | 1.0485 | loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
27.1A Cx | CDH1 | -0.988068 | 1.0083 | loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
27.1A Cx | ZFHX3 | -0.988068 | 1.0083 | loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
27.1A Cx | FANCA | -0.988068 | 1.0083 | loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
27.1A Cx | SMAD2 | -0.96199 | 1.0267 | loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
27.1A Cx | MBD1 | -0.96199 | 1.0267 | loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
Clinical Information
Sample Number | 27.1A |
---|---|
Sample Site | Brain |
Sample source | Autopsy |
Pathology Tumor Diagnosis | Adenocarcinoma |
Gleason Score | None |
Primary Gleason Score | None |
Secondary Gleason Score | None |
Tertiary Gleason Score | None |
ISUP Grade Group | |
Tumor Grade | |
D'Amico Risk Classification | |
Tumor Volume (in cc) | 0.0 |
Treatment Prior to Specimen Collection | ADT, docetaxel, abiraterone |
Patient Information
Patient Number | 27 |
---|---|
Sex | Male |
Diagnosis | Prostate Cancer |
PSA at diagnosis (ng/mL) | 42 |
Consent to share data | |
Patient Tumor Collection (Current Model) | |
---|---|
Tumour sample ID | 27.1A |
Patient Age (binned in 5 year age groups) | 70-74 |
This table displays curated sequence variants
The table can be sorted by any field. However, please note that when you click on a column header to sort, there might be a brief delay
The table can be sorted by any field. However, please note that when you click on a column header to sort, there might be a brief delay
PDX ID | Gene Symbol | Depth | ALT_FREQ | Consequence | Exon | GnomAD_AF | CADD_PHRED | Clinvar_clnsig | Platform | Experiments Name | Reference | Library Type | Instrument Type |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
27.1A Cx | PCDH11X | 187 | 1.0 | missense_variant | '2/7 | . | 22.9 | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
27.1A Cx | TH | 372 | 0.61 | start_lost | '1/14 | . | 21.5 | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
27.1A Cx | TH | 372 | 0.61 | start_lost | '1/14 | . | 21.5 | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
27.1A Cx | LHFPL3 | 516 | 0.53 | missense_variant | '1/5 | . | 26.7 | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
27.1A Cx | SON | 395 | 0.51 | missense_variant | '3/12 | . | 25.4 | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
27.1A Cx | IGF2R | 655 | 0.39 | missense_variant | '16/48 | 3.28E-05 | 24 | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
27.1A Cx | NF1 | 464 | 0.28 | stop_gained | '40/58 | . | 38 | Pathogenic | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
No information in Gene expression
No information in Drug dosing Table